We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$4.5B
Cap. Flow
% of AUM
10.34%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,819
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$424M |
| 2 |
Kenvue
KVUE
|
+$415M |
| 3 |
Cummins
CMI
|
+$374M |
| 4 |
Bunge Global
BG
|
+$310M |
| 5 |
Newell Brands
NWL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$423M |
| 2 |
Qualcomm
QCOM
|
+$413M |
| 3 |
D.R. Horton
DHI
|
+$401M |
| 4 |
Booking.com
BKNG
|
+$397M |
| 5 |
Phillips 66
PSX
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 12.39% |
| 4 | Healthcare | 10.91% |
| 5 | Technology | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWI
1326
DELISTED
SolarWinds Corporation Common Stock
SWI
| $33.6K | ﹤0.01% |
2,664
+1,996
| +299% | +$24.3K |
|
1327
Tower Semiconductor
TSEM
$22.9B
| $33.4K | ﹤0.01% |
998
-36
| -3% | -$1.12K |
|
1328
Viridian Therapeutics
VRDN
$2.15B
| $33.3K | ﹤0.01% |
+1,900
| New | +$36.8K |
|
|
INBX
1329
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $32.9K | ﹤0.01% |
+942
| New | +$34.4K |
|
1330
ImmunityBio
IBRX
$7.3B
| $32.7K | ﹤0.01% |
+6,097
| New | +$27.6K |
|
1331
Protagonist Therapeutics
PTGX
$8.8B
| $32.2K | ﹤0.01% |
+1,113
| New | +$30.3K |
|
1332
C4 Therapeutics
CCCC
$393M
| $32.1K | ﹤0.01% |
+3,929
| New | +$30.5K |
|
1333
Veracyte
VCYT
$4.44B
| $31.8K | ﹤0.01% |
+1,437
| New | +$35.1K |
|
1334
JFrog
FROG
$9.26B
| $31.8K | ﹤0.01% |
720
-24
| -3% | -$929 |
|
1335
Global E Online
GLBE
$6.53B
| $31.5K | ﹤0.01% |
866
-32
| -4% | -$1.19K |
|
1336
Mirum Pharmaceuticals
MIRM
$6.84B
| $31.1K | ﹤0.01% |
+1,240
| New | +$34.1K |
|
1337
Kura Oncology
KURA
$826M
| $30.9K | ﹤0.01% |
+1,451
| New | +$28.2K |
|
1338
NetEase
NTES
$81.5B
| $30.7K | ﹤0.01% |
297
+117
| +65% | +$12K |
|
1339
Agios Pharmaceuticals
AGIO
$2.14B
| $30.1K | ﹤0.01% |
+1,031
| New | +$27.6K |
|
1340
Arcus Biosciences
RCUS
$3.4B
| $29.8K | ﹤0.01% |
+1,579
| New | +$27.3K |
|
1341
Disc Medicine
IRON
$2.85B
| $29.7K | ﹤0.01% |
+477
| New | +$30.9K |
|
1342
Scholar Rock
SRRK
$5.92B
| $28.6K | ﹤0.01% |
+1,612
| New | +$25.4K |
|
1343
Corcept Therapeutics
CORT
$10.1B
| $28.3K | ﹤0.01% |
1,124
-173
| -13% | -$4.09K |
|
1344
Semtech
SMTC
$10.4B
| $28.3K | ﹤0.01% |
1,028
+781
| +316% | +$16.7K |
|
1345
Mesa Laboratories
MLAB
$559M
| $28.2K | ﹤0.01% |
257
+135
| +111% | +$13.6K |
|
1346
Cabaletta Bio
CABA
$445M
| $28.2K | ﹤0.01% |
+1,653
| New | +$35.5K |
|
1347
Editas Medicine
EDIT
$402M
| $27.8K | ﹤0.01% |
+3,748
| New | +$31.1K |
|
1348
3D Systems Corp
DDD
$412M
| $27.8K | ﹤0.01% |
6,262
| – | – |
|
|
VERV
1349
DELISTED
Verve Therapeutics
VERV
| $26.7K | ﹤0.01% |
+2,013
| New | +$26.7K |
|
1350
Gogo Inc
GOGO
$550M
| $26.3K | ﹤0.01% |
2,992
+1,737
| +138% | +$15.6K |
|
Similar funds
SAM
Pacer Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Pacer Advisors held 3,819 positions worth $43.5B, up 23% from $35.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $4.5B of net new capital in Q1 2024, opening 249 new positions and adding to 1,063 existing holdings. Its largest new stake was Hanesbrands: 32,772,533 shares worth $190M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 19% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $423M trimmed.
- Pacer Advisors's largest Q1 2024 buy was Hanesbrands: 32,772,533 shares worth $190M.
- Pacer Advisors added most to AT&T in Q1 2024, an estimated $424M increase.
- Pacer Advisors's biggest Q1 2024 reduction was AbbVie, cutting an estimated $423M.
- Pacer Advisors fully exited Tri Pointe Homes in Q1 2024, selling an estimated $139M.
- Pacer Advisors's ten largest holdings make up 12% of its $43.5B portfolio in Q1 2024.
- Pacer Advisors opened 249 new positions and closed 119 in Q1 2024.
- Pacer Advisors's portfolio value rose 23% quarter-over-quarter to $43.5B.
Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.